Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Over 4M options to the board...

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Dec 15, 2022 8:12am

126 Views

Post# 35172659

RE:RE:RE:RE:RE:RE:RE:RE:RE:Over 4M options to the board...

jimsenior wrote: Ongoing/Cancer Accelerated Approvals - (AA)

As of 12/13/2022 there were 67 Trials

I cannot be absolutely certain, but I did not see any pancreatic cancer trials in the above noted group.

Many thanks. Still dreaming for an epic run for the SP. Probably coming faster than we think. GL

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing